[1]
|
Tezel, G., Timur, S.S., Bozkurt, İ., Türkoğlu, Ö.F., Eroğlu, İ., Nemutlu, E., et al. (2019) A Snapshot on the Current Status of Alzheimer’s Disease, Treatment Perspectives, in-vitro and in-vivo Research Studies and Future Opportunities. Chemical and Pharmaceutical Bulletin, 67, 1030-1041. https://doi.org/10.1248/cpb.c19-00511
|
[2]
|
柯欢, 韩贇, 王淑婵, 等. 阿尔茨海默病病人家庭照顾者哀伤干预研究进展[J]. 护理研究, 2023, 37(18): 3344-3347.
|
[3]
|
Leng, F. and Edison, P. (2020) Neuroinflammation and Microglial Activation in Alzheimer Disease: Where Do We Go from Here? Nature Reviews Neurology, 17, 157-172. https://doi.org/10.1038/s41582-020-00435-y
|
[4]
|
汪盛, 李越然, 刘俊, 等. 阿尔茨海默病诊断和治疗研究进展[J]. 中国药理学与毒理学杂志, 2023, 37(7): 490.
|
[5]
|
张莹林, 姚俊岩. 神经炎症在阿尔茨海默病中作用的研究进展[J]. 国际麻醉学与复苏杂志, 2022, 43(1): 90-94.
|
[6]
|
康晨瑶, 刘洲, 周海红. NLRP3炎症小体在AD发病机制中的作用[J]. 医学信息, 2021, 34(12): 40-43.
|
[7]
|
时建铨, 徐俊. NLRP3炎症小体: 阿尔茨海默病炎症反应核心机制及潜在靶点[J]. 中国现代神经疾病杂志, 2020, 20(1): 29-33.
|
[8]
|
王彩红, 魏晓涛, 赵永强, 等. NLRP3炎症小体在认知功能障碍相关疾病防治中的作用及中药干预研究进展[J]. 中国中药杂志, 2024, 49(4): 902-911.
|
[9]
|
欣宇, 周妍妍, 王琪, 等. 中医药干预NLRP3信号通路防治阿尔茨海默病的研究进展[J]. 中国实验方剂学杂志, 2024, 30(8): 290-298.
|
[10]
|
Reddy, P.H. and Oliver, D.M. (2019) Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease. Cells, 8, Article 488. https://doi.org/10.3390/cells8050488
|
[11]
|
潘文亮, 江宁, 王松, 等. 甲型流感病毒与NLRP3炎性小体激活的研究进展[J]. 畜牧与兽医, 2021, 53(4): 132-138.
|
[12]
|
高洋, 秦合伟, 李彦杰. NLRP3炎症小体在阿尔兹海默症中的作用及潜在治疗靶点[J]. 中国生物化学与分子生物学报, 2024, 40(1): 18-27.
|
[13]
|
Busche, M.A. and Hyman, B.T. (2020) Synergy between Amyloid-Β and Tau in Alzheimer’s Disease. Nature Neuroscience, 23, 1183-1193. https://doi.org/10.1038/s41593-020-0687-6
|
[14]
|
Chang, C., Shao, E. and Mucke, L. (2021) Tau: Enabler of Diverse Brain Disorders and Target of Rapidly Evolving Therapeutic Strategies. Science, 371, eabb8255. https://doi.org/10.1126/science.abb8255
|
[15]
|
Neddens, J., Temmel, M., Flunkert, S., Kerschbaumer, B., Hoeller, C., Loeffler, T., et al. (2018) Phosphorylation of Different Tau Sites during Progression of Alzheimer’s Disease. Acta Neuropathologica Communications, 6, Article No. 52. https://doi.org/10.1186/s40478-018-0557-6
|
[16]
|
Wang, Z., Wang, Q., Li, S., Li, X., Yang, W. and He, D. (2023) Microglial Autophagy in Alzheimer’s Disease and Parkinson’s Disease. Frontiers in Aging Neuroscience, 14, Article 1065183. https://doi.org/10.3389/fnagi.2022.1065183
|
[17]
|
Stefanoska, K., Gajwani, M., Tan, A.R.P., Ahel, H.I., Asih, P.R., Volkerling, A., et al. (2022) Alzheimer’s Disease: Ablating Single Master Site Abolishes Tau Hyperphosphorylation. Science Advances, 8, eabl8809. https://doi.org/10.1126/sciadv.abl8809
|
[18]
|
Stancu, I., Cremers, N., Vanrusselt, H., Couturier, J., Vanoosthuyse, A., Kessels, S., et al. (2019) Aggregated Tau Activates NLRP3-ASC Inflammasome Exacerbating Exogenously Seeded and Non-Exogenously Seeded Tau Pathology in Vivo. Acta Neuropathologica, 137, 599-617. https://doi.org/10.1007/s00401-018-01957-y
|
[19]
|
Milner, M.T., Maddugoda, M., Götz, J., Burgener, S.S. and Schroder, K. (2021) The NLRP3 Inflammasome Triggers Sterile Neuroinflammation and Alzheimer’s Disease. Current Opinion in Immunology, 68, 116-124. https://doi.org/10.1016/j.coi.2020.10.011
|
[20]
|
Hanslik, K.L. and Ulland, T.K. (2020) The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer’s Disease. Frontiers in Neurology, 11, Article 570711. https://doi.org/10.3389/fneur.2020.570711
|
[21]
|
Vande Walle, L., Stowe, I.B., Šácha, P., Lee, B.L., Demon, D., Fossoul, A., et al. (2019) MCC950/CRID3 Potently Targets the NACHT Domain of Wild-Type NLRP3 but Not Disease-Associated Mutants for Inflammasome Inhibition. PLOS Biology, 17, e3000354. https://doi.org/10.1371/journal.pbio.3000354
|
[22]
|
Tousif, S., Singh, A.P., Umbarkar, P., Galindo, C., Wheeler, N., Toro Cora, A., et al. (2023) Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation. Circulation Research, 132, 267-289. https://doi.org/10.1161/circresaha.122.321504
|
[23]
|
Jiang, H., He, H., Chen, Y., Huang, W., Cheng, J., Ye, J., et al. (2017) Identification of a Selective and Direct NLRP3 Inhibitor to Treat Inflammatory Disorders. Journal of Experimental Medicine, 214, 3219-3238. https://doi.org/10.1084/jem.20171419
|
[24]
|
Lunding, L.P., Skouras, D.B., Vock, C., Dinarello, C.A. and Wegmann, M. (2021) The NLRP3 Inflammasome Inhibitor, Olt1177®, Ameliorates Experimental Allergic Asthma in Mice. Allergy, 77, 1035-1038. https://doi.org/10.1111/all.15164
|
[25]
|
Amo-Aparicio, J., Garcia-Garcia, J., Puigdomenech, M., Francos-Quijorna, I., Skouras, D.B., Dinarello, C.A., et al. (2022) Inhibition of the NLRP3 Inflammasome by OLT1177 Induces Functional Protection and Myelin Preservation after Spinal Cord Injury. Experimental Neurology, 347, Article 113889. https://doi.org/10.1016/j.expneurol.2021.113889
|
[26]
|
Huang, Y., Jiang, H., Chen, Y., Wang, X., Yang, Y., Tao, J., et al. (2018) Tranilast Directly Targets NLRP 3 to Treat Inflammasome‐Driven Diseases. EMBO Molecular Medicine, 10, e8689. https://doi.org/10.15252/emmm.201708689
|
[27]
|
Chen, S., Wang, Y., Pan, Y., Liu, Y., Zheng, S., Ding, K., et al. (2020) Novel Role for Tranilast in Regulating NLRP3 Ubiquitination, Vascular Inflammation, and Atherosclerosis. Journal of the American Heart Association, 9, e015513. https://doi.org/10.1161/jaha.119.015513
|
[28]
|
He, H., Jiang, H., Chen, Y., Ye, J., Wang, A., Wang, C., et al. (2018) Oridonin Is a Covalent NLRP3 Inhibitor with Strong Anti-Inflammasome Activity. Nature Communications, 9, Article No. 2550. https://doi.org/10.1038/s41467-018-04947-6
|
[29]
|
宋小叶, 庞心怡, 陆颖健. 萝卜硫素在神经系统疾病领域的研究进展[J]. 食品科学, 2023, 44(3): 332-340.
|
[30]
|
刘超越. 异甘草素抑制癫痫发生中NLRP3/CASPASE-1/GSDMD参与的神经元损伤[D]: [硕士学位论文]. 济南: 山东大学, 2023.
|
[31]
|
Wu, Y., Teng, Y., Zhang, C., Pan, Y., Zhang, Q., Zhu, X., et al. (2022) The Ketone Body Β-Hydroxybutyrate Alleviates Cocrmo Alloy Particles Induced Osteolysis by Regulating NLRP3 Inflammasome and Osteoclast Differentiation. Journal of Nanobiotechnology, 20, Article No. 120. https://doi.org/10.1186/s12951-022-01320-0
|
[32]
|
高萍, 蒋莉, 邱梦露, 等. 小白菊内酯通过抑制NLRP3/caspase-1/IL-1β信号通路减轻哮喘幼年大鼠气道炎症[J]. 中国优生与遗传杂志, 2023, 31(6): 1177-1182.
|
[33]
|
Filippone, A., Scuderi, S.A., Basilotta, R., Lanza, M., Casili, G., Bova, V., et al. (2022) BAY-117082-Driven NLRP3 Inflammasome Inhibition Resolves Nitro-Glycerine (NTG) Neuronal Damage in in Vivo Model of Migraine. Biomedicine & Pharmacotherapy, 156, Article 113851. https://doi.org/10.1016/j.biopha.2022.113851
|